Recombinant human follicle-stimulating hormone treatment leads to normal follicular growth, estradiol secretion, and pregnancy in a World Health Organization group II anovulatory woman.
A first case of successful induction of ovulation with recombinant human FSH administered subcutaneously to a WHO group II anovulatory patient is reported. Using a chronic low-dose protocol, recombinant human FSH, a preparation with no LH activity, led to a clear and even supraphysiological increase of inhibin and E2 and the development of four follicles among which one was dominant. The treatment cycle resulted in an ongoing pregnancy.
Hornnes
P
P
Department of Obstetrics and Gynecology, University Hospital, Copenhagen, Denmark.
Giroud
D
D
Howles
C
C
Loumaye
E
E
D000328:Adult; D000858:Anovulation / Q000145:classification / Q000188:drug therapy* / Q000503:physiopathology*; D004958:Estradiol / Q000097:blood / Q000378:metabolism*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use*; D006801:Humans; D009765:Obesity / Q000150:complications; D006080:Ovarian Follicle / Q000502:physiology*; D011085:Polycystic Ovary Syndrome / Q000150:complications; D011247:Pregnancy; D011994:Recombinant Proteins; D012016:Reference Values; D014944:World Health Organization
D011994:Recombinant Proteins; D004958:Estradiol; D005640:Follicle Stimulating Hormone